{
  "success": true,
  "pagesUsed": [
    2,
    3,
    6,
    12,
    14
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "SYNOPSIS",
        "text": "SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "SYNOPSIS",
        "sectionType": {
          "id": "5f0728b3-2ba0-4b2f-8a8f-573f3ade5715",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "995121d2-bb35-4f60-80a4-80044600a3bb",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3",
          "nci_2_4",
          "nci_2_5",
          "nci_2_6"
        ]
      },
      {
        "id": "nc_3",
        "name": "STUDY OBJECTIVES",
        "text": "STUDY OBJECTIVES",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY OBJECTIVES",
        "sectionType": {
          "id": "25b65ce4-330b-43b8-9a55-57c52235cfcb",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_3_1",
          "nci_3_2",
          "nci_3_3",
          "nci_3_4",
          "nci_3_5"
        ]
      },
      {
        "id": "nc_4",
        "name": "INVESTIGATIONAL PLAN",
        "text": "INVESTIGATIONAL PLAN",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "INVESTIGATIONAL PLAN",
        "sectionType": {
          "id": "09df035c-7a40-4d51-9e63-4d1689abe924",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2",
          "nci_4_3",
          "nci_4_4",
          "nci_4_5",
          "nci_4_6",
          "nci_4_7",
          "nci_4_8",
          "nci_4_9",
          "nci_4_10"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_2_1",
        "name": "PHARMACOLOGY OF BIVV009",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "PHARMACOLOGY OF BIVV009"
      },
      {
        "id": "nci_2_2",
        "name": "BACKGROUND AND STUDY RATIONALE",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "BACKGROUND AND STUDY RATIONALE"
      },
      {
        "id": "nci_2_3",
        "name": "Non-clinical experience",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2.1",
        "sectionTitle": "Non-clinical experience"
      },
      {
        "id": "nci_2_4",
        "name": "Clinical experience",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2.2",
        "sectionTitle": "Clinical experience"
      },
      {
        "id": "nci_2_5",
        "name": "Pharmacokinetic experience and dose justification",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2.3",
        "sectionTitle": "Pharmacokinetic experience and dose justification"
      },
      {
        "id": "nci_2_6",
        "name": "Potential risks and benefits",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2.4",
        "sectionTitle": "Potential risks and benefits"
      },
      {
        "id": "nci_3_1",
        "name": "PRIMARY OBJECTIVE (PART A)",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "PRIMARY OBJECTIVE (PART A)"
      },
      {
        "id": "nci_3_2",
        "name": "SECONDARY OBJECTIVES (PART A)",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "SECONDARY OBJECTIVES (PART A)"
      },
      {
        "id": "nci_3_3",
        "name": "PRIMARY OBJECTIVE (PART B)",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3",
        "sectionTitle": "PRIMARY OBJECTIVE (PART B)"
      },
      {
        "id": "nci_3_4",
        "name": "SECONDARY OBJECTIVE (PART B)",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.4",
        "sectionTitle": "SECONDARY OBJECTIVE (PART B)"
      },
      {
        "id": "nci_3_5",
        "name": "EXPLORATORY OBJECTIVE (PART B)",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.5",
        "sectionTitle": "EXPLORATORY OBJECTIVE (PART B)"
      },
      {
        "id": "nci_4_1",
        "name": "STUDY DESIGN",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "STUDY DESIGN"
      },
      {
        "id": "nci_4_2",
        "name": "DISCUSSION OF STUDY DESIGN",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "DISCUSSION OF STUDY DESIGN"
      },
      {
        "id": "nci_4_3",
        "name": "STUDY ENDPOINTS",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "STUDY ENDPOINTS"
      },
      {
        "id": "nci_4_4",
        "name": "Primary endpoint (Part A)",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.1",
        "sectionTitle": "Primary endpoint (Part A)"
      },
      {
        "id": "nci_4_5",
        "name": "Secondary efficacy endpoints (Part A)",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.2",
        "sectionTitle": "Secondary efficacy endpoints (Part A)"
      },
      {
        "id": "nci_4_6",
        "name": "Exploratory efficacy endpoints (Part A)",
        "text": "",
        "order": 5,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.3",
        "sectionTitle": "Exploratory efficacy endpoints (Part A)"
      },
      {
        "id": "nci_4_7",
        "name": "Efficacy endpoints (Part B)",
        "text": "",
        "order": 6,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.4",
        "sectionTitle": "Efficacy endpoints (Part B)"
      },
      {
        "id": "nci_4_8",
        "name": "Safety Endpoints",
        "text": "",
        "order": 7,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.5",
        "sectionTitle": "Safety Endpoints"
      },
      {
        "id": "nci_4_9",
        "name": "Pharmacokinetic Endpoints",
        "text": "",
        "order": 8,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.6",
        "sectionTitle": "Pharmacokinetic Endpoints"
      },
      {
        "id": "nci_4_10",
        "name": "Pharmacodynamic Endpoints",
        "text": "",
        "order": 9,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3.7",
        "sectionTitle": "Pharmacodynamic Endpoints"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "ADA",
        "expandedText": "antidrug antibody",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "ADL",
        "expandedText": "activities of daily living",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "AE",
        "expandedText": "adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "AMR",
        "expandedText": "antibody-mediated rejection",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "AUC",
        "expandedText": "area under the concentration-time curve",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "BLA",
        "expandedText": "Biologics License Application",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "BP",
        "expandedText": "bullous pemphigoid",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "CAgD",
        "expandedText": "cold agglutinin disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "CFR",
        "expandedText": "Code of Federal Regulations",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "CI",
        "expandedText": "confidence interval",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "CIC",
        "expandedText": "circulating immune complex",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "Cmax",
        "expandedText": "maximum observed concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "CP",
        "expandedText": "complement classical pathway",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "CRO",
        "expandedText": "Clinical Research Organization",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "CTCAE",
        "expandedText": "common terminology criteria for adverse events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "DAT",
        "expandedText": "direct antiglobulin test",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "DNA",
        "expandedText": "deoxyribonucleic acid",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "dsDNA",
        "expandedText": "double-stranded DNA",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "EC",
        "expandedText": "Ethics Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "ECG",
        "expandedText": "electrocardiogram",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "eCRF",
        "expandedText": "electronic Case Report Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "EDC",
        "expandedText": "electronic data capture",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "EOS",
        "expandedText": "end of study",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "EOT",
        "expandedText": "end of treatment",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "EQ-5D-5L",
        "expandedText": "five level EuroQol - five dimensions questionnaire",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "ET",
        "expandedText": "early termination",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "FACIT",
        "expandedText": "functional assessment of chronic illness therapy",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "FAX",
        "expandedText": "facsimile",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "FDA",
        "expandedText": "Food and Drug Administration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "FIH",
        "expandedText": "first in human",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "FAS",
        "expandedText": "Full Analysis Set",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "GCP",
        "expandedText": "Good Clinical Practice",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_33",
        "abbreviatedText": "Hgb",
        "expandedText": "hemoglobin",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_34",
        "abbreviatedText": "HIV",
        "expandedText": "human immunodeficiency virus",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_35",
        "abbreviatedText": "IB",
        "expandedText": "investigator’s brochure",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_36",
        "abbreviatedText": "ICF",
        "expandedText": "informed consent form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_37",
        "abbreviatedText": "ICH",
        "expandedText": "International Council for Harmonisation",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_38",
        "abbreviatedText": "IM",
        "expandedText": "intramuscularly",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_39",
        "abbreviatedText": "IRB",
        "expandedText": "Institutional Review Board",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_40",
        "abbreviatedText": "ITT",
        "expandedText": "intent-to-treat",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_41",
        "abbreviatedText": "IUD",
        "expandedText": "intrauterine device",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_42",
        "abbreviatedText": "IV",
        "expandedText": "intravenous",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_43",
        "abbreviatedText": "LDH",
        "expandedText": "lactate dehydrogenase",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_44",
        "abbreviatedText": "LPO",
        "expandedText": "last patient out",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_45",
        "abbreviatedText": "MAA",
        "expandedText": "Market Authorization Application",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_46",
        "abbreviatedText": "PK",
        "expandedText": "Pharmacokinetic",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_47",
        "abbreviatedText": "PD",
        "expandedText": "Pharmacodynamic",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_48",
        "abbreviatedText": "QOL",
        "expandedText": "quality of life",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 4,
      "itemCount": 21,
      "abbreviationCount": 48
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "Cardinal Study: A Phase 3, pivotal, open-label, multicenter study to assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease who have a recent history of blood transfusion",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amended Clinical Trial Protocol 06",
      "versionDate": "19-Dec-2019",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "ADA",
          "expansion": "antidrug antibody"
        },
        {
          "abbreviation": "ADL",
          "expansion": "activities of daily living"
        },
        {
          "abbreviation": "AE",
          "expansion": "adverse event"
        },
        {
          "abbreviation": "AMR",
          "expansion": "antibody-mediated rejection"
        },
        {
          "abbreviation": "AUC",
          "expansion": "area under the concentration-time curve"
        },
        {
          "abbreviation": "BLA",
          "expansion": "Biologics License Application"
        },
        {
          "abbreviation": "BP",
          "expansion": "bullous pemphigoid"
        },
        {
          "abbreviation": "CAgD",
          "expansion": "cold agglutinin disease"
        },
        {
          "abbreviation": "CFR",
          "expansion": "Code of Federal Regulations"
        },
        {
          "abbreviation": "CI",
          "expansion": "confidence interval"
        },
        {
          "abbreviation": "CIC",
          "expansion": "circulating immune complex"
        },
        {
          "abbreviation": "Cmax",
          "expansion": "maximum observed concentration"
        },
        {
          "abbreviation": "CP",
          "expansion": "complement classical pathway"
        },
        {
          "abbreviation": "CRO",
          "expansion": "Clinical Research Organization"
        },
        {
          "abbreviation": "CTCAE",
          "expansion": "common terminology criteria for adverse events"
        },
        {
          "abbreviation": "DAT",
          "expansion": "direct antiglobulin test"
        },
        {
          "abbreviation": "DNA",
          "expansion": "deoxyribonucleic acid"
        },
        {
          "abbreviation": "dsDNA",
          "expansion": "double-stranded DNA"
        },
        {
          "abbreviation": "EC",
          "expansion": "Ethics Committee"
        },
        {
          "abbreviation": "ECG",
          "expansion": "electrocardiogram"
        },
        {
          "abbreviation": "eCRF",
          "expansion": "electronic Case Report Form"
        },
        {
          "abbreviation": "EDC",
          "expansion": "electronic data capture"
        },
        {
          "abbreviation": "EOS",
          "expansion": "end of study"
        },
        {
          "abbreviation": "EOT",
          "expansion": "end of treatment"
        },
        {
          "abbreviation": "EQ-5D-5L",
          "expansion": "five level EuroQol - five dimensions questionnaire"
        },
        {
          "abbreviation": "ET",
          "expansion": "early termination"
        },
        {
          "abbreviation": "FACIT",
          "expansion": "functional assessment of chronic illness therapy"
        },
        {
          "abbreviation": "FAX",
          "expansion": "facsimile"
        },
        {
          "abbreviation": "FDA",
          "expansion": "Food and Drug Administration"
        },
        {
          "abbreviation": "FIH",
          "expansion": "first in human"
        },
        {
          "abbreviation": "FAS",
          "expansion": "Full Analysis Set"
        },
        {
          "abbreviation": "GCP",
          "expansion": "Good Clinical Practice"
        },
        {
          "abbreviation": "Hgb",
          "expansion": "hemoglobin"
        },
        {
          "abbreviation": "HIV",
          "expansion": "human immunodeficiency virus"
        },
        {
          "abbreviation": "IB",
          "expansion": "investigator’s brochure"
        },
        {
          "abbreviation": "ICF",
          "expansion": "informed consent form"
        },
        {
          "abbreviation": "ICH",
          "expansion": "International Council for Harmonisation"
        },
        {
          "abbreviation": "IM",
          "expansion": "intramuscularly"
        },
        {
          "abbreviation": "IRB",
          "expansion": "Institutional Review Board"
        },
        {
          "abbreviation": "ITT",
          "expansion": "intent-to-treat"
        },
        {
          "abbreviation": "IUD",
          "expansion": "intrauterine device"
        },
        {
          "abbreviation": "IV",
          "expansion": "intravenous"
        },
        {
          "abbreviation": "LDH",
          "expansion": "lactate dehydrogenase"
        },
        {
          "abbreviation": "LPO",
          "expansion": "last patient out"
        },
        {
          "abbreviation": "MAA",
          "expansion": "Market Authorization Application"
        },
        {
          "abbreviation": "PK",
          "expansion": "Pharmacokinetic"
        },
        {
          "abbreviation": "PD",
          "expansion": "Pharmacodynamic"
        },
        {
          "abbreviation": "QOL",
          "expansion": "quality of life"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "Cardinal Study: A Phase 3, pivotal, open-label, multicenter study to assess the efficacy and safety of BIVV009 in patients with primary cold agglutinin disease who have a recent history of blood transfusion",
        "version": "Amended Clinical Trial Protocol 06",
        "versionDate": "19-Dec-2019"
      },
      "sections": [
        {
          "number": "1",
          "title": "SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "2",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "2.1",
              "title": "PHARMACOLOGY OF BIVV009"
            },
            {
              "number": "2.2",
              "title": "BACKGROUND AND STUDY RATIONALE"
            },
            {
              "number": "2.2.1",
              "title": "Non-clinical experience"
            },
            {
              "number": "2.2.2",
              "title": "Clinical experience"
            },
            {
              "number": "2.2.3",
              "title": "Pharmacokinetic experience and dose justification"
            },
            {
              "number": "2.2.4",
              "title": "Potential risks and benefits"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY OBJECTIVES",
          "type": "Objectives",
          "subsections": [
            {
              "number": "3.1",
              "title": "PRIMARY OBJECTIVE (PART A)"
            },
            {
              "number": "3.2",
              "title": "SECONDARY OBJECTIVES (PART A)"
            },
            {
              "number": "3.3",
              "title": "PRIMARY OBJECTIVE (PART B)"
            },
            {
              "number": "3.4",
              "title": "SECONDARY OBJECTIVE (PART B)"
            },
            {
              "number": "3.5",
              "title": "EXPLORATORY OBJECTIVE (PART B)"
            }
          ]
        },
        {
          "number": "4",
          "title": "INVESTIGATIONAL PLAN",
          "type": "Study Design",
          "subsections": [
            {
              "number": "4.1",
              "title": "STUDY DESIGN"
            },
            {
              "number": "4.2",
              "title": "DISCUSSION OF STUDY DESIGN"
            },
            {
              "number": "4.3",
              "title": "STUDY ENDPOINTS"
            },
            {
              "number": "4.3.1",
              "title": "Primary endpoint (Part A)"
            },
            {
              "number": "4.3.2",
              "title": "Secondary efficacy endpoints (Part A)"
            },
            {
              "number": "4.3.3",
              "title": "Exploratory efficacy endpoints (Part A)"
            },
            {
              "number": "4.3.4",
              "title": "Efficacy endpoints (Part B)"
            },
            {
              "number": "4.3.5",
              "title": "Safety Endpoints"
            },
            {
              "number": "4.3.6",
              "title": "Pharmacokinetic Endpoints"
            },
            {
              "number": "4.3.7",
              "title": "Pharmacodynamic Endpoints"
            }
          ]
        }
      ]
    }
  }
}